Quadrature Capital Ltd Invests $1.41 Million in Chemed Co. (NYSE:CHE)

Quadrature Capital Ltd bought a new stake in Chemed Co. (NYSE:CHE - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,348 shares of the company's stock, valued at approximately $1,411,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of CHE. GAMMA Investing LLC increased its stake in Chemed by 34.4% in the second quarter. GAMMA Investing LLC now owns 86 shares of the company's stock valued at $47,000 after purchasing an additional 22 shares during the period. Ballentine Partners LLC increased its position in Chemed by 4.1% in the 3rd quarter. Ballentine Partners LLC now owns 655 shares of the company's stock valued at $394,000 after acquiring an additional 26 shares during the period. Everpar Advisors LLC raised its stake in Chemed by 4.9% during the 2nd quarter. Everpar Advisors LLC now owns 580 shares of the company's stock valued at $315,000 after acquiring an additional 27 shares during the last quarter. Creative Planning lifted its position in Chemed by 2.8% during the 2nd quarter. Creative Planning now owns 1,228 shares of the company's stock worth $667,000 after acquiring an additional 34 shares during the period. Finally, First Heartland Consultants Inc. grew its stake in shares of Chemed by 7.2% in the 3rd quarter. First Heartland Consultants Inc. now owns 508 shares of the company's stock valued at $305,000 after purchasing an additional 34 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company's stock.

Chemed Price Performance

NYSE CHE traded down $3.41 on Friday, hitting $552.62. 81,657 shares of the company's stock were exchanged, compared to its average volume of 78,987. The firm's 50-day moving average price is $574.95 and its two-hundred day moving average price is $564.94. The firm has a market cap of $8.32 billion, a price-to-earnings ratio of 27.92, a P/E/G ratio of 2.42 and a beta of 0.46. Chemed Co. has a fifty-two week low of $523.33 and a fifty-two week high of $654.62.

Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $5.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.76 by ($0.12). The business had revenue of $606.18 million during the quarter, compared to analysts' expectations of $612.22 million. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.32 EPS. On average, research analysts predict that Chemed Co. will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, December 6th. Shareholders of record on Monday, November 18th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Monday, November 18th. This represents a $2.00 annualized dividend and a yield of 0.36%. Chemed's payout ratio is currently 10.11%.

Insiders Place Their Bets

In other Chemed news, EVP Nicholas Michael Westfall sold 1,713 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $569.35, for a total value of $975,296.55. Following the sale, the executive vice president now owns 6,109 shares of the company's stock, valued at approximately $3,478,159.15. This represents a 21.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $598.81, for a total value of $1,197,620.00. Following the transaction, the chief executive officer now directly owns 103,735 shares of the company's stock, valued at $62,117,555.35. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,845 shares of company stock worth $3,978,798. 3.32% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on CHE. Royal Bank of Canada decreased their price target on Chemed from $697.00 to $633.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research report on Saturday, November 30th.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.